| name | Olmesartan |
| classification | Angiotensin II Receptor Antagonist (ARA-II) / Angiotensin II Blocker |
| pharmacokinetics | Olmesartan is primarily metabolized by the liver. The drug is well absorbed following oral administration, with peak plasma concentrations typically achieved within 1-2 hours. Its elimination half-life is around 14 hours, making once-daily dosing a common practice. Renal excretion of the metabolite, and some of the parent drug, is important to consider in patients with renal impairment. |
| suggested dosage | The typical starting dose for olmesartan medoxomil is 20 mg once daily. Dosage may be adjusted upward to a maximum of 40 mg, based on individual patient response and blood pressure control. Consult a physician for specific dosage recommendations. |
| indications | Olmesartan is primarily used for the treatment of hypertension (high blood pressure). It may also be used in combination with other antihypertensive medications to achieve blood pressure control in patients who do not respond adequately to monotherapy. |
| safety in pregnancy | Olmesartan should be used with caution in pregnant women. Data on its use during pregnancy is limited, and potential risks to the developing fetus are unknown. Olmesartan is not generally recommended during pregnancy unless the potential benefit clearly outweighs the potential risk. Consult a physician regarding appropriate alternatives if pregnancy is suspected or planned. |
| safety in breastfeeding | Limited data on olmesartan secretion into breast milk is available. Therefore, use of olmesartan during breastfeeding is not generally recommended. Alternative treatments should be explored where possible. If used, close monitoring of the infant for any potential adverse effects is important. |
| side effects | | 1 | Dizziness | | 2 | Headache | | 3 | Fatigue | | 4 | Lightheadedness | | 5 | Hypotension (low blood pressure) | | 6 | Nasal congestion | | 7 | Cough | | 8 | Diarrhea | | 9 | Nausea | | 10 | Vomiting | | 11 | Kidney problems (rare) | | 12 | Elevated liver enzymes (rare) |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to olmesartan or any of its components | | 2 | Severe bilateral renal artery stenosis | | 3 | Severe hepatic impairment | | 4 | Concurrent use of aliskiren-containing medications in patients with diabetes or renal impairment (due to potential risk of renal dysfunction) |
|
| interactions | Olmesartan can interact with other medications, such as diuretics, potassium-sparing diuretics, ACE inhibitors, NSAIDs, and some other antihypertensives. Tell your doctor about all medications you are taking. |
| warnings and precautions | Patients with renal impairment may require dosage adjustments. Monitor renal function closely, especially during initiation of therapy. Patients with a history of angioedema should be closely monitored. Caution should be used in patients with heart failure, though use is often appropriate with careful monitoring. |
| additional informations | Olmesartan is a commonly prescribed and effective medication for hypertension. It is generally well tolerated. However, individual responses to the medication vary and careful monitoring by a healthcare professional is crucial. |
| patient specific details | | age | 25 | | weight | 70 kg | | notes | The provided age and weight are common for a young male adult and aren't factors directly affecting olmesartan dosage in most cases. Always consult a physician for personalized treatment plans. |
|
